PPARG and irritable bowel syndrome: Pioglitazone can inhibit visceral allodynia and increase colonic permeability, but the PPARγ antagonist GW9662 completely reverses the effect of pioglitazone, indicating that pioglitazone may be used for irritable bowel syndrome (IBS) treatment [102] by activating PPARγ.